A recent study in lymphoma, showed that HDAC6 plays an oncogenic role in DLBCL and the combination of ricolinostat with crizotinib (ALK inhibitor) generated a strong synergistic effects. Here, HDAC6 is linked to diffuse large B-cell lymphoma.